NCT07091500

Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

Effect of GLP-1 Receptor Agonist Therapy With and Without Exercise Training on Muscle Mass and Physical Function in People With Obesity

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 50 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The use of glucagon-like peptide receptor agonists (GLP-1 RAs) may have clinically important effects on skeletal muscle mass (SMM), and physical function. The effects of exercise training in conjunction with GLP-1 RA therapy on these outcomes has not been studied. Additionally, most people treated with GLP-1-based weight loss medications stop taking these medications within 1 year of initiating treatment. This is an important clinical concern because weight regain can occur after weight loss pharmacotherapy is stopped and the impact of stopping GLP-1 RA therapy on physical and metabolic function has not been studied. In this study, the investigators will conduct a 2-year randomized clinical trial to evaluate body composition, muscle physical and metabolic function, and muscle strength in response to GLP-1 RA therapy, with or without exercise training, and subsequent treatment cessation on muscle-related outcomes.

Conditions

• Obesity
• Skeletal Muscle

Interventions

Type	Name	Description
BEHAVIORAL	Exercise training	Participants will perform supervised exercise training sessions 3 days per week and unsupervised at-home sessions 2-3 days per week.
DRUG	Semaglutide	semaglutide 2.4 mg subcutaneous per week or max tolerated dose and diet behavior counseling

Timeline

• Start date: 2025-08-11
• Primary completion: 2028-08-01
• Completion: 2029-08-01
• First posted: 2025-07-29
• Last updated: 2025-09-23

Locations

1 site across 1 country: United States